NextPoint Therapeutics Stock

nextpointtx.comHealthcare / BioTech & PharmaFounded: 2020

NextPoint Therapeutics is a biotechnology company specializing in new treatments for patients diagnosed with various forms of cancer. Headquartered in Cambridge, Massachusetts, the company leads fieldwork and clinical development on the novel HHLA2 pathway to deliver a new class of monotherapies for patients who may not benefit from other forms of inhibitors.

Register To Buy and Sell Shares

For more details on financing and valuation for NextPoint Therapeutics, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access NextPoint Therapeutics’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like NextPoint Therapeutics.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Register

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Ivan Cheung
Chief Executive Officer
Tatiana Novobrantseva Ph.D
Chief Scientific Officer
Paul Conrad Ph.D
Chief Business Officer
Leena Gandhi MD Ph.D
Chief Medical Officer

Board Members

Ansbert Gadicke MD
MPM BioImpact
Matthew Roden Ph.D
MPM BioImpact
Rakhshita Dhar
Leaps by Bayer
R. Jacob Vogelstein Ph.D
Catalio Capital Management

Frequently Asked Questions About NextPoint Therapeutics’ Stock

plusminus
Can you buy NextPoint Therapeutics’ stock?
NextPoint Therapeutics is not publicly traded on NYSE or NASDAQ in the U.S. To buy NextPoint Therapeutics’ stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
plusminus
Can you sell NextPoint Therapeutics’ stock?
Yes, you can sell stock of a private company like NextPoint Therapeutics. Forge can help you sell your NextPoint Therapeutics stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
plusminus
What is NextPoint Therapeutics’ stock price?
NextPoint Therapeutics is a privately held company and therefore does not have a public stock price. However, you may access NextPoint Therapeutics’ private market stock price with Forge Data.
plusminus
What is NextPoint Therapeutics’ stock ticker symbol?
NextPoint Therapeutics does not have an official ticker symbol because this company is not currently publicly traded.
plusminus
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

NextPoint Therapeutics Raises $42.5M; Closes $122.5M Series B Financing
NexPoint raised $122.5 million in a recent series B funding round to continue developing their oncology drugs.
NextPoint Therapeutics Announces Closing of Series B Financing Extension Led by Catalio Capital Management
NextPoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision oncology therapeutics targeting the novel HHLA2 pathway, announced today the closing of a $42.5M Extension to its Series B financing round resulting in a total of $122.5M raised in the Series B financing. The funds will be used to advance the company’s two immuno-oncology clinical programs, NPX267 and NPX887, as well as propel the development of additional therapeutic modalities in the pipeline that target the novel HHLA2 tumor antigen.
NextPoint Therapeutics Announces $80 Million Series B Financing co-led by Leaps by Bayer and Sanofi Ventures to Advance Novel Immuno-Oncology Programs
Programs target the novel HHLA2 pathway, activating anti-tumor immune responses to find and destroy cancer cells
Updated on: May 23, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.